| Primary |
| Prostate Cancer Metastatic |
19.6% |
| Prostate Cancer |
19.5% |
| Product Used For Unknown Indication |
13.3% |
| Drug Use For Unknown Indication |
8.1% |
| Antiandrogen Therapy |
5.2% |
| Drug Exposure During Pregnancy |
5.1% |
| Neoplasm |
4.3% |
| Fungal Infection |
3.3% |
| Hypertension |
2.8% |
| Onychomycosis |
2.5% |
| Cushing's Syndrome |
2.2% |
| Hypercholesterolaemia |
1.9% |
| Enzyme Inhibition |
1.6% |
| Pituitary-dependent Cushing's Syndrome |
1.6% |
| Ill-defined Disorder |
1.5% |
| Skin Lesion |
1.5% |
| Tinea Pedis |
1.5% |
| Fungal Skin Infection |
1.3% |
| Hiv Infection |
1.3% |
| Tinea Infection |
1.3% |
|
| Off Label Use |
25.0% |
| Drug Interaction |
11.6% |
| Vomiting |
11.6% |
| Rhabdomyolysis |
9.9% |
| Urticaria |
4.1% |
| Rash |
3.5% |
| Renal Failure Acute |
3.5% |
| Liver Disorder |
2.9% |
| Nausea |
2.9% |
| Weight Decreased |
2.9% |
| Anaphylactoid Reaction |
2.3% |
| Hepatic Failure |
2.3% |
| Hepatitis Cholestatic |
2.3% |
| Premature Baby |
2.3% |
| Prostatic Specific Antigen Increased |
2.3% |
| Pruritus |
2.3% |
| Suicidal Ideation |
2.3% |
| Transaminases Increased |
2.3% |
| Acute Generalised Exanthematous Pustulosis |
1.7% |
| Adrenocortical Insufficiency Acute |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
36.6% |
| Prostate Cancer |
15.5% |
| Drug Use For Unknown Indication |
10.8% |
| Hypertension |
8.3% |
| Neoplasm |
5.6% |
| Pain |
3.3% |
| Prostate Cancer Metastatic |
2.6% |
| Muscle Spasms |
1.6% |
| Neoplasm Malignant |
1.6% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Cushing's Syndrome |
1.5% |
| Pruritus |
1.5% |
| Trichophytosis |
1.4% |
| Hypercholesterolaemia |
1.3% |
| Pulmonary Mycosis |
1.3% |
| Depression |
1.2% |
| Cortisol Free Urine Increased |
1.1% |
| Fungal Infection |
1.1% |
| Dyslipidaemia |
1.0% |
| Rheumatoid Arthritis |
1.0% |
|
| Rhabdomyolysis |
15.4% |
| Drug Interaction |
8.9% |
| Vestibular Disorder |
8.9% |
| Vomiting |
8.1% |
| Neutropenic Sepsis |
6.5% |
| White Blood Cell Count Decreased |
4.9% |
| Asthenia |
4.1% |
| Drug Ineffective |
4.1% |
| Renal Failure Acute |
4.1% |
| Urosepsis |
4.1% |
| Hair Texture Abnormal |
3.3% |
| Myositis |
3.3% |
| Nervousness |
3.3% |
| Pulmonary Oedema |
3.3% |
| Renal Failure |
3.3% |
| Septic Shock |
3.3% |
| Surgery |
3.3% |
| Weight Increased |
3.3% |
| Anxiety |
2.4% |
| Deep Vein Thrombosis |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.2% |
| Drug Use For Unknown Indication |
14.9% |
| Hypertension |
7.5% |
| Prostate Cancer |
7.2% |
| Hiv Infection |
6.9% |
| Pain |
4.6% |
| Psoriasis |
3.3% |
| Eczema |
2.4% |
| Metastases To Bone |
2.2% |
| Multiple Myeloma |
2.2% |
| Prophylaxis |
2.1% |
| Rash |
2.1% |
| Depression |
1.9% |
| Rheumatoid Arthritis |
1.8% |
| Diabetes Mellitus |
1.7% |
| Osteoporosis |
1.7% |
| Insomnia |
1.6% |
| Acne |
1.5% |
| Anxiety |
1.5% |
| Type 2 Diabetes Mellitus |
1.4% |
|
| Weight Decreased |
21.1% |
| Vomiting |
10.2% |
| Visual Impairment |
5.6% |
| Pulmonary Embolism |
5.0% |
| Tooth Fracture |
5.0% |
| Weight Increased |
5.0% |
| Wound |
5.0% |
| Pyrexia |
4.7% |
| Death |
4.4% |
| Type 2 Diabetes Mellitus |
3.8% |
| Urinary Tract Infection |
3.8% |
| Wound Infection Staphylococcal |
3.5% |
| Pancreatitis |
3.2% |
| Swelling |
3.2% |
| Syncope |
2.9% |
| Wheezing |
2.9% |
| Wound Infection |
2.9% |
| Fatigue |
2.6% |
| Pain |
2.6% |
| Pneumonia |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
24.8% |
| Post-traumatic Epilepsy |
12.4% |
| Prolactinoma |
11.0% |
| Respiratory Tract Infection |
6.9% |
| Vulvovaginal Mycotic Infection |
6.9% |
| Immunosuppressant Drug Therapy |
4.1% |
| Prostate Cancer Metastatic |
4.1% |
| Hypertension |
3.4% |
| Skin Lesion |
3.4% |
| Dyslipidaemia |
2.8% |
| Prostate Cancer |
2.8% |
| Urinary Tract Infection |
2.8% |
| Cancer Pain |
2.1% |
| Constipation |
2.1% |
| Hypercholesterolaemia |
2.1% |
| Hypokalaemia |
2.1% |
| Obsessive-compulsive Disorder |
2.1% |
| Cushing's Syndrome |
1.4% |
| Drug Level Below Therapeutic |
1.4% |
| Dysmenorrhoea |
1.4% |
|
| Drug Interaction |
21.6% |
| Renal Failure Acute |
8.1% |
| Breast Discomfort |
5.4% |
| Diplopia |
5.4% |
| Loss Of Consciousness |
5.4% |
| Mental Status Changes |
5.4% |
| Mucosal Dryness |
5.4% |
| Psychomotor Hyperactivity |
5.4% |
| Rhabdomyolysis |
5.4% |
| Toxicity To Various Agents |
5.4% |
| Abdominal Discomfort |
2.7% |
| Abnormal Behaviour |
2.7% |
| Abnormal Weight Gain |
2.7% |
| Apparent Death |
2.7% |
| Drug Level Increased |
2.7% |
| Haemorrhage |
2.7% |
| Headache |
2.7% |
| Hepatic Failure |
2.7% |
| Liver Disorder |
2.7% |
| Metastatic Neoplasm |
2.7% |
|
